2018 American Transplant Congress
Decreased Long-Term Survival with Antithymocyte Globulin Induction in Elderly Kidney Transplant Recipients
Henry Ford Transplant Institute, Detroit, MI.
Purpose: Long-term consequences of immunosuppression on the elderly is still unclear. This data to evaluates long-term outcomes for younger (Y) versus elderly (E) kidney transplant…2018 American Transplant Congress
Cost Effectiveness of Lifelong Medicare Immunosuppressant Drug Coverage for Kidney Transplant Recipients in the Current Era
While there is no Medicare time limit for dialysis patients, kidney transplant recipients lose their Medicare coverage 36 months after they receive their transplant. The…2018 American Transplant Congress
Survival Advantage from Accepting a Circulatory Death Liver Transplant
Background As liver failure increases in the UK, so does demand for liver transplantation. In response, UK donation after circulatory death (DCD) activity has approximately…2018 American Transplant Congress
Long-Term Nonhuman Primate Renal Allograft Survival without Ongoing Immunosuppression in Recipients of Delayed Donor Bone Marrow Transplantation
Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.
Background: We have previously reported induction of renal allograft tolerance in nonhuman primates following an initial post-transplant period of conventional immunosuppression (IS) using a nonmyeloablative…2018 American Transplant Congress
Intention to Treat Outcomes of Patients with Hepatocellular Carcinoma Downstaged to within Milan
Objectives: The success of LRT has served as a tool to select a subgroup of patients exceeding transplant criteria but potentially achieving meaningful outcome with…2018 American Transplant Congress
First-Time Simultaneous vs. Sequential Liver-Kidney Transplantation in Polycystic Kidney Disease: A Review of the UNOS Database
1Baylor College of Medicine, Houston, TX; 2Texas Children's Hospital, Houston, TX.
Introduction. Polycystic disease (PKD) may necessitate the need for liver and/or kidney transplantation. The long-term outcomes of simultaneous liver-kidney transplantation (SLK) and kidney-after-liver (KAL) or…2018 American Transplant Congress
Comparing Outcomes between Induction Immunosuppressive Therapies in Simultaneous Liver/Kidney Transplantation
Virginia Commonwealth University, Richmond, VA.
Introduction: There is no data on the risks and benefits of induction immunosuppression in simultaneous liver/kidney transplant (SLKT) patients.Methods: We analyzed all SLKT performed between…2018 American Transplant Congress
Thymoglobulin Induction Decreases Risk of Death in HLA-Sensitized Kidney Recipients
Paris Translational Research Center for Organ Transplantation, Paris, France.
Anti-thymocyte globulin (ATG) is currently the preferential induction treatment in kidney recipients at high risk for allograft rejection. However, no study has evaluated the benefits…2018 American Transplant Congress
Significant Alteration in Transplant Center Performance Assessment with Extended Patient Follow Up Time
IntroductionCurrent transplant center performance models focus on 1-year graft and patient survival as primary outcomes. This is despite that 2.5 year cohorts are used to…2018 American Transplant Congress
Contemporary Practice Patterns & Outcomes after Transjugular Intrahepatic Portosystemic Shunt (TIPS) Placement: A Multicenter US Experience of 1,146 Patients
Background: TIPS is effective for treating complications of portal hypertension. Historic, single center data suggest poor outcomes for MELD scores >15. We assessed contemporary outcomes…
American Transplant Congress abstracts